Bright Minds Biosciences Inc.

DRUG Nasdaq SEC CIK 1827401
Follow Bright Minds Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2024 CAD · IFRS
Net income −CAD 2.8M +62% vs prior year
EPS, diluted −CAD 0.65 +67.2% vs prior year
Operating cash flow −CAD 1.9M +73.7% vs prior year
Net income by fiscal year
−CAD 480.4K
−CAD 8.7M
−CAD 15M
−CAD 7.4M
−CAD 2.8M
FY20 FY21 FY22 FY23 FY24

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income7 fiscal years
−CAD 15M−CAD 10M−CAD 5MCAD 0FY18FY19FY20FY21FY22FY23FY24
Show the numbers
YearNet income
FY24−CAD 2.8M
FY23−CAD 7.4M
FY22−CAD 15M
FY21−CAD 8.7M
FY20−CAD 480.4K
FY19-
FY18-